Commission Delegated Regulation (EU) 2024/197 of 19 October 2023 amending Regulation (EC) No 1272/2008 as regards the harmonised classification and labelling of certain substances
This is the act as published. Later amendments are not folded into the text below: each one is a separate act in this repository and an entry in this law's history.
| Image omitted; see official source | Official Journal of the European Union | EN Series L |
| --- | --- | --- |
| 2024/197 | 5.1.2024 |
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 [^ntr1-L_202400197EN.000101-E0001], and in particular Article 37(5) thereof,
Whereas:
- (1) Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation.
- (2) Proposals to introduce harmonised classification and labelling of certain substances and to update the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (the ‘Agency’) pursuant to Article 37 of Regulation (EC) No 1272/2008. The Committee for Risk Assessment of the Agency (RAC) adopted, after having taken account of the comments received from the parties concerned, the following opinions [^ntr2-L_202400197EN.000101-E0002] on those proposals:
- — Opinion of 18 March 2021 concerning benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate;
- — Opinion of 18 March 2021 concerning benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis[phenol] (1:1);
- — Opinion of 18 March 2021 concerning reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (1:1);
- — Opinion of 18 March 2021 concerning reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol (1:1);
- — Opinion of 18 March 2021 concerning 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol; bisphenol AF;
- — Opinion of 18 March 2021 concerning cinnamaldehyde; 3-phenylprop-2-enal; cinnamic aldehyde; cinnamal [1], (2E)-3-phenylprop-2-enal [2];
- — Opinion of 18 March 2021 concerning benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluoro-2,6-dinitro-p-toluidine;
- — Opinion 18 March 2021 concerning 3,3'-dimethylbiphenyl-4,4'-diyl diisocyanate;
- — Opinion of 18 March 2021 concerning foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N-dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea;
- — Opinion of 18 March 2021 concerning ethyl acrylate;
- — Opinion of 18 March 2021 concerning methyl acrylate;
- — methyl propenoate;
- — Opinion of 18 March 2021 concerning methyl methacrylate; methyl 2-methylprop-2-enoate; methyl 2-methylpropenoate;
- — Opinion of 18 March 2021 concerning transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate;
- — Opinion of 18 March 2021 concerning allyl methacrylate; 2-methyl-2-propenoic acid 2-propenyl ester;
- — Opinion of 18 March 2021 concerning mepiquat chloride (ISO); 1,1-dimethylpiperidinium chloride;
- — Opinion of 10 June 2021 concerning triethylamine;
- — Opinion of 10 June 2021 concerning di-n-butylamine;
- — Opinion of 10 June 2021 concerning 4-nitrosomorpholine;
- — Opinion of 10 June 2021 concerning difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether;
- — Opinion 10 June 2021 concerning N,N-dimethyl-p-toluidine;
- — Opinion of 10 June 2021 concerning potassium chlorate;
- — Opinion of 10 June 2021 concerning sodium chlorate;
- — Opinion of 10 June 2021 Concerning reaction mass of 1-(2,3-epoxypropoxy)-2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane;
- — Opinion of 10 June 2021 concerning metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one;
- — Opinion 16 September 2021 concerning lithium carbonate [1] lithium chloride [2] lithium hydroxide [3];
- — Opinion of 16 September 2021 concerning dimethyl propylphosphonate;
- — Opinion of 16 September 2021 concerning dibutyltin maleate;
- — Opinion of 16 September 2021 concerning dibutyltin oxide;
- — Opinion of 16 September 2021 concerning clothianidin (ISO); (E)-1-(2-chloro-1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine;
- — Opinion of 16 September 2021 concerning cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide;
- — Opinion of 16 September 2021 concerning nonylphenol, branched and linear, ethoxylated (with average molecular weight < 352 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof];
- — Opinion of 16 September 2021 concerning nonylphenol, branched and linear, ethoxylated (with 352 g/mol ≤ average molecular weight < 704 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof];
- — Opinion of 16 September 2021 concerning nonylphenol, branched and linear, ethoxylated (with 704 g/mol ≤ average molecular weight ≤ 1 540 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof];
- — Opinion of 16 September 2021 concerning 1-phenylethan-1-one (1-phenylethylidene)hydrazone;
- — Opinion of 16 September 2021 concerning 9-[2-(ethoxycarbonyl)phenyl]-3,6-bis(ethylamino)-2,7-dimethylxanthylium chloride; Basic Red 1;
- — Opinion of 16 September 2021 concerning picolinafen (ISO); N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide; 4′-fluoro-6-[(α,α,α-trifluoro-m-tolyl)oxy]picolinanilide;
- — Opinion of 16 September 2021 concerning diuron (ISO); 3-(3,4-dichlorophenyl)-1,1-dimethylurea;
- — Opinion of 16 September 2021 concerning diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide;
- — Opinion of 16 September 2021 concerning hydrogen sulphide, hydrogen sulfide;
- — Opinion of 16 September 2021 concerning benzyl alcohol;
- — Opinion of 16 September 2021 concerning resorcinol; 1,3-benzenediol;
- — Opinion of 16 September 2021 concerning 2,2',6,6'-tetrabromo-4,4'-isopropylidenediphenol; tetrabromobisphenol-A;
- — Opinion of 16 September 2021 concerning a reassessment at the request of the Commission to review the harmonised classification of lead (environment);
- — Opinion of 26 November 2021 concerning 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bisethanol;
- — Opinion of 26 November 2021 concerning 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol;
- — Opinion of 26 November 2021 concerning 1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs.; Reaction mass of N-phenyl,N’-o-tolyl-phenylene diamine, N,N’-diphenyl-p-phenylene diamine and N,N’-di-o-tolyl-phenylene diamine;
- — Opinion of 26 November 2021 concerning tetramethylene dimethacrylate;
- — Opinion of 26 November 2021 concerning 7,7,9(or 7,9,9)-trimethyl-4,13-dioxo-3,14-dioxa-5,12-diazahexadecane-1,16-diyl bismethacrylate;
- — Opinion of 26 November 2021 concerning 2,2'-ethylenedioxydiethyl dimethacrylate;
- — Opinion of 26 November 2021 concerning bifenox (ISO); methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate;
- — Opinion of 26 November 2021 concerning 4-methylimidazole;
- — Opinion of 26 November 2021 concerning sulfur dioxide;
- — Opinion of 26 November 2021 concerning 1,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3-one;
- — Opinion of 26 November 2021 concerning benalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate.
- (3) The Commission has received additional information from stakeholders contesting the scientific assessment set out in the RAC opinion of 26 November 2021 concerning 1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs. and in the RAC opinion of 16 September 2021 concerning dibutyltin oxide. The additional information has been assessed and has not been found sufficient to cast doubts on the scientific analysis contained in the RAC opinions. It is therefore appropriate to introduce the harmonised classification and labelling of the substances concerned on the basis of the assessment made in those opinions.
- (4) The RAC opinion of 16 September 2021 concerning the environmental toxicity of lead put forward various possible options to update the harmonised classification of lead for aquatic toxicity. These options give the possibility to either have a single entry for both lead in powder form (‘lead powder’) and in massive form (‘lead massive’) or to keep two separate entries, one for each form. However, as data for lead massive indicates a lower dissolution in water than for lead powder, a calculation in accordance with Part 4 of Annex I to Regulation (EC) No 1272/2008 leads to a less severe classification for lead massive. It is therefore appropriate to amend the existing aquatic toxicity classification for lead powder with regard to the M-factor and to introduce a different aquatic toxicity classification for lead massive.
- (5) In light of the RAC opinions, it is therefore appropriate to introduce or update the harmonised classification and labelling of the substances concerned on the basis of the assessment made in those opinions and following the further assessments.
- (6) Regulation (EC) No 1272/2008 should therefore be amended accordingly.
- (7) As regards the classification of methyl methacrylate as a respiratory sensitiser and the classification of lithium carbonate, lithium chloride and lithium hydroxide as reproductive toxic substances the Commission has received additional information from stakeholders after obtaining the RAC opinions of 18 March 2021 and of 16 September 2021 respectively concerning those substances. Since that new scientific information requires further assessment by RAC, methyl methacrylate, lithium carbonate, lithium chloride and lithium hydroxide recommended in the RAC opinions should not be subject to harmonised classification and labelling at this stage.
- (8) Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or updated classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Suppliers should, however, have the possibility to apply the new or updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of this Regulation, to ensure a high level of protection of human health and of the environment and to provide sufficient flexibility to suppliers,
HAS ADOPTED THIS REGULATION:
Article 1
Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.
Article 2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
It shall apply from 1 September 2025.
However, suppliers may already before that date classify, label and package substances and mixtures in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 19 October 2023.
For the Commission
The President
Ursula VON DER LEYEN
[^ntr1-L_202400197EN.000101-E0001]: OJ L 353, 31.12.2008, p. 1.
[^ntr2-L_202400197EN.000101-E0002]: The opinions are accessible via the following website: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/.The opinion of 16 September 2021 concerning a reassessment at the request of the Commission is accessible via the following website: https://echa.europa.eu/about-us/who-we-are/committee-for-risk-assessment/opinions-of-the-rac-adopted-under-specific-echa-s-executive-director-requests.
ANNEX
In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:
- (1) the following entries are inserted following the order of the index numbers corresponding to each entry:
| Index No | Chemical Name | EC No | CAS No | Classification | Classification | Labelling | Labelling | Labelling | Specific Conc. Limits, M- factors and ATE | Notes |
|---|---|---|---|---|---|---|---|---|---|---|
| Index No | Chemical Name | EC No | CAS No | Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | Specific Conc. Limits, M- factors and ATE | Notes |
| ‘015-204-00-5 | benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate | 479-100-5 | 577705-90-9 | Repr. 1B | H360F | GHS08 Dgr | H360F’ | |||
| ‘015-205-00-0 | benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis[phenol] (1:1) | 278-305-5 | 75768-65-9 | Repr. 1B | H360F | GHS08 Dgr | H360F’ | |||
| ‘015-206-00-6 | reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (1:1) | — | — | Repr. 1B | H360F | GHS08 Dgr | H360F’ | |||
| ‘015-207-00-1 | reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol (1:1) | — | — | Repr. 1B | H360F | GHS08 Dgr | H360F’ | |||
| ‘015-208-00-7 | dimethyl propylphosphonate | 242-555-3 | 18755-43-6 | Muta. 1B Repr. 1B | H340 H360Df | GHS08 Dgr | H340 H360Df’ | |||
| ‘050-034-00-5 | dibutyltin maleate | 201-077-5 | 78-04-6 | Muta. 2 Repr. 1B Acute Tox. 2 Acute Tox. 4 STOT RE 1 Skin Corr. 1 Eye Dam. 1 | H341 H360FD H330 H302 H372 (immune system) H314 H318 | GHS08 GHS06 GHS05 Dgr | H341 H360FD H330 H302 H372 (immune system) H314 | inhalation: ATE = 0,317 mg/L (dusts or mists) oral: ATE = 510 mg/kg bw’ | ||
| ‘050-035-00-0 | dibutyltin oxide | 212-449-1 | 818-08-6 | Muta. 2 Repr. 1B Acute Tox. 3 STOT RE 1 Skin Irrit. 2 Eye Dam. 1 | H341 H360FD H301 H372 (immune system) H315 H318 | GHS08 GHS06 GHS05 Dgr | H341 H360FD H301 H372 (immune system) H315 H318 | oral: ATE = 170 mg/kg bw’ | ||
| ‘603-244-00-1 | reaction mass of 1-(2,3-epoxypropoxy)–2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane | — | — | Muta. 2 Repr. 1B | H341 H360F | GHS08 Dgr | H341 H360F’ | |||
| ‘603-245-00-7 | 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bisethanol | 221-665-5 | 3179-89-3 | Skin Sens. 1 | H317 | GHS07 Wng | H317’ | |||
| ‘603-246-00-2 | 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol | 211-477-1 | 647-42-7 | STOT RE 2 Aquatic Chronic 1 | H373 (teeth, bones) H410 | GHS08 GHS09 Wng | H373 (teeth, bones) H410 | M = 1’ | ||
| ‘604-099-00-7 | 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol; bisphenol AF | 216-036-7 | 1478-61-1 | Repr. 1B | H360F | GHS08 Dgr | H360F’ | |||
| ‘604-100-00-0 | nonylphenol, branched and linear, ethoxylated (with average molecular weight ≤ 1 540 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof] | 500-315-8 500-024-6 500-045-0 500-209-1 248-762-5 243-816-4 248-291-5 — 230-770-5 248-743-1 247-555-7 248-293-6 — and others | 127087-87-0 9016-45-9 26027-38-3 68412-54-4 27986-36-3 20427-84-3 27176-93-8 1119449-38-5 7311-27-5 27942-27-4 26264-02-8 27177-05-5 14409-72-4 and others | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 1 M = 10’ | ||
| ‘606-155-00-6 | cinnamaldehyde; 3-phenylprop-2-enal; cinnamic aldehyde; cinnamal; [1] (2E)-3-phenylprop-2-enal [2] | 203-213-9 [1] - [2] | 104-55-2 [1] 14371-10-9 [2] | Skin Sens. 1A | H317 | GHS07 Wng | H317 | Skin Sens. 1; H317: C ≥ 0,01 %’ | ||
| ‘607-766-00-0 | tetramethylene dimethacrylate | 218-218-1 | 2082-81-7 | Skin Sens. 1B | H317 | GHS07 Wng | H317’ | |||
| ‘607-767-00-6 | 7,7,9(or 7,9,9)-trimethyl–4,13-dioxo–3,14-dioxa–5,12-diazahexadecane–1,16-diyl bismethacrylate | 276-957-5 | 72869-86-4 | Skin Sens. 1B | H317 | GHS07 Wng | H317’ | |||
| ‘607-768-00-1 | 2,2'-ethylenedioxydiethyl dimethacrylate | 203-652-6 | 109-16-0 | Skin Sens. 1B | H317 | GHS07 Wng | H317’ | |||
| ‘607-769-00-7 | bifenox (ISO); methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate | 255-894-7 | 42576-02-3 | Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Wng | H302 H410 | oral: ATE = 1 500 mg/kg bw M = 1 000 M = 1 000 ’ | ||
| ‘612-295-00-9 | benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluoro-2,6-dinitro-p-toluidine | 217-465-2 | 1861-40-1 | Carc. 2 Repr. 2 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H361d H315 H319 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H361d H315 H319 H317 H410 | M = 10 M = 10’ | ||
| ‘612-296-00-4 | N,N-dimethyl-p-toluidine | 202-805-4 | 99-97-8 | Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT RE 2 Aquatic Chronic 3 | H350 H332 H301 H373 (blood system, respiratory tract) H412 | GHS08 GHS06 Dgr | H350 H332 H301 H373 (blood system, respiratory tract) H412 | inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 140 mg/kg bw’ | ||
| ‘612-297-00-X | 1-phenylethan-1-one (1-phenylethylidene)hydrazone | 211-979-0 | 729-43-1 | Skin Sens. 1 | H317 | GHS07 Wng | H317’ | |||
| ‘612-298-00-5 | 1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs.; | 273-227-8 | 68953-84-4 | Repr. 1B Skin Sens. 1 | H360FD H317 | GHS08 GHS07 Dgr | H360FD H317’ | |||
| ‘613-346-00-8 | 4-nitrosomorpholine | — | 59-89-2 | Carc. 1B Muta. 2 STOT RE 1 | H350 H341 H372 (liver) | GHS08 Dgr | H350 H341 H372 (liver) | Carc. 1B; H350: C ≥ 0,001 %’ | ||
| ‘613-347-00-3 | difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl–1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether | — | 119446-68-3 | Carc. 2 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H319 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H302 H319 H410 | oral: ATE = 1 450 mg/kg bw M = 10 M = 10’ | ||
| ‘613-348-00-9 | 9-[2-(ethoxycarbonyl)phenyl]–3,6-bis(ethylamino)–2,7-dimethylxanthylium chloride; Basic Red 1 | 213-584-9 | 989-38-8 | Acute Tox. 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H301 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Dgr | H301 H318 H317 H410 | oral: ATE = 280 mg/kg bw M = 10 M = 1’ | ||
| ‘613-349-00-4 | 4-methylimidazole | 212-497-3 | 822-36-6 | Carc. 1B Repr. 1B | H350 H360Fd | GHS08 Dgr | H350 H360Fd’ | |||
| ‘615-051-00-X | 3,3'-dimethylbiphenyl–4,4'-diyl diisocyanate | 202-112-7 | 91-97-4 | Carc. 2 Resp. Sens. 1 Skin Sens. 1A | H351 H334 H317 | GHS08 Dgr | H351 H334 H317 | Skin Sens. 1A; H317: C ≥ 0,001 %’ | ||
| ‘616-241-00-5 | foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N-dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea | — | 173159-57-4 | Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 | H351 H400 H410 | GHS08 GHS09 Wng | H351 H410 | M = 1 000 M = 100’ | ||
| ‘616-242-00-0 | picolinafen (ISO); N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide; 4′-fluoro-6-[(α,α,α-trifluoro-m-tolyl)oxy]picolinanilide | — | 137641-05-5 | STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H373 (blood system, thyroid) H400 H410 | GHS08 GHS09 Wng | H373 (blood system, thyroid) H410 | M = 1 000 M = 1 000 ’ |
- (2) the entries corresponding to index numbers 006-015-00-9; 015-203-00-X; 016-001-00-4; 016-011-00-9; 017-004-00-3; 017-005-00-9; 082-013-00-1; 082-014-00-7; 603-057-00-5; 604-010-00-1; 604-074-00-0; 606-034-00-8; 607-032-00-X; 607-034-00-0; 607-223-00-8; 607-246-00-3; 612-004-00-5; 612-049-00-0; 612-056-00-9; 613-088-00-6; 613-127-00-7; 613-307-00-5; 616-035-00-5; 616-104-00-X are replaced by the following entries respectively:
| Index No | Chemical Name | EC No | CAS No | Classification | Classification | Labelling | Labelling | Labelling | Specific Conc. Limits, M-factors and ATE | Notes |
|---|---|---|---|---|---|---|---|---|---|---|
| Index No | Chemical Name | EC No | CAS No | Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | Specific Conc. Limits, M-factors and ATE | Notes |
| ‘006-015-00-9 | diuron (ISO); 3-(3,4-dichlorophenyl)–1,1-dimethylurea | 206-354-4 | 330-54-1 | Carc. 1B STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H350 H373 (blood system) H400 H410 | GHS08 GHS09 Dgr | H350 H373 (blood system) H410 | M = 100 M = 100’ | ||
| ‘015-203-00-X | diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide | 278-355-8 | 75980-60-8 | Repr. 1B Skin Sens. 1B | H360Fd H317 | GHS08 GHS07 Dgr | H360Fd H317’ | |||
| ‘016-001-00-4 | hydrogen sulphide, hydrogen sulfide | 231-977-3 | 7783-06-4 | Flam. Gas 1A Press. Gas Acute Tox. 2 Aquatic Acute 1 | H220 H330 H400 | GHS02 GHS06 GHS09 Dgr | H220 H330 H400 | inhalation: ATE = 440 ppmV (gases) | U’ | |
| ‘016-011-00-9 | sulphur dioxide; sulfur dioxide | 231-195-2 | 7446-09-5 | Press. Gas Acute Tox. 3 STOT SE 1 Skin. Corr. 1B | H331 H370 (respiratory system) (inhalation) H314 | GHS04 GHS06 GHS08 GHS05 Dgr | H331 H370 (respiratory system) (inhalation) H314 | inhalation: ATE = 1 000 ppmV (gases) | U, 5’ | |
| ‘017-004-00-3 | potassium chlorate | 223-289-7 | 3811-04-9 | Ox. Sol. 1 Acute Tox. 3 | H271 H301 | GHS03 GHS06 Dgr | H271 H301 | oral: ATE = 100 mg/kg bw’ | ||
| ‘017-005-00-9 | sodium chlorate | 231-887-4 | 7775-09-9 | Ox. Sol. 1 Acute Tox. 3 | H271 H301 | GHS03 GHS06 Dgr | H271 H301 | oral: ATE = 100 mg/kg bw’ | ||
| ‘082-013-00-1 | lead powder; [particle diameter < 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1 | H360FD H362 H400 H410 | GHS08 GHS09 Dgr | H360FD H362 H410 | Repr. 1A; H360D: C ≥ 0,03 % M = 10 M = 100’ | ||
| ‘082-014-00-7 | lead massive: [particle diameter ≥ 1 mm] | 231-100-4 | 7439-92-1 | Repr. 1A Lact. Aquatic Chronic 1 | H360FD H362 H410 | GHS08 GHS09 Dgr | H360FD H362 H410 | M = 10’ | ||
| ‘603-057-00-5 | benzyl alcohol | 202-859-9 | 100-51-6 | Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1B | H302 H319 H317 | GHS07 Wng | H302 H319 H317 | oral: ATE = 1 200 mg/kg bw’ | ||
| ‘604-010-00-1 | resorcinol; 1,3-benzenediol | 203-585-2 | 108-46-3 | Acute Tox. 4 STOT SE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1B Aquatic Acute 1 | H302 H370 (nervous system) H315 H319 H317 H400 | GHS07 GHS08 GHS09 Dgr | H302 H370 (nervous system) H315 H319 H317 H400 | oral: ATE = 500 mg/kg bw M = 1’ | ||
| ‘604-074-00-0 | 2,2',6,6'-tetrabromo–4,4'-isopropylidenediphenol; tetrabromobisphenol-A | 201-236-9 | 79-94-7 | Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 | H350 H400 H410 | GHS08 GHS09 Dgr | H350 H410’ | |||
| ‘606-034-00-8 | metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one | 244-209-7 | 21087-64-9 | Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H302 H373 (blood system) H400 H410 | GHS07 GHS08 GHS09 Wng | H302 H373 (blood system) H410 | oral: ATE = 320 mg/kg bw M = 10 M = 10’ | ||
| ‘607-032-00-X | ethyl acrylate | 205-438-8 | 140-88-5 | Flam. Liq. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 | H225 H331 H312 H302 H335 H315 H319 H317 | GHS02 GHS06 Dgr | H225 H331 H312 H302 H335 H315 H319 H317 | inhalation: ATE = 9 mg/L (vapours) dermal: ATE = 1 800 mg/kg bw oral: ATE = 1 120 mg/kg bw STOT SE 3; H335: C ≥ 5 % Skin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % | D’ | |
| ‘607-034-00-0 | methyl acrylate; methyl propenoate | 202-500-6 | 96-33-3 | Flam. Liq. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 | H225 H331 H312 H302 H335 H315 H319 H317 | GHS02 GHS06 Dgr | H225 H331 H312 H302 H335 H315 H319 H317 | inhalation: ATE = 3 mg/L (vapours) dermal: ATE = 1 100 mg/kg bw oral: ATE = 500 mg/kg bw | D’ | |
| ‘607-223-00-8 | transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate | 405-060-5 | 118712-89-3 | Carc. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H302 H370 (nervous system) H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H302 H370 (nervous system) H410 | EUH066 | oral: ATE = 580 mg/kg bw M = 1 000 M = 1 000 ’ | |
| ‘607-246-00-3 | allyl methacrylate; 2-methyl-2-propenoic acid 2-propenyl ester | 202-473-0 | 96-05-9 | Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 | H226 H330 H311 H302 H400 | GHS02 GHS06 GHS09 Dgr | H226 H330 H311 H302 H400 | inhalation: ATE = 1,5 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 400 mg/kg bw’ | ||
| ‘612-004-00-5 | triethylamine | 204-469-4 | 121-44-8 | Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1A Eye Dam. 1 | H225 H331 H311 H301 H314 H318 | GHS02 GHS06 GHS05 Dgr | H225 H331 H311 H301 H314 | inhalation: ATE = 7,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 100 mg/kg bw STOT SE 3; H335: C ≥ 1 %’ | ||
| ‘612-049-00-0 | di-n-butylamine | 203-921-8 | 111-92-2 | Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 | H226 H330 H311 H301 H314 H318 | GHS02 GHS06 GHS05 Dgr | H226 H330 H311 H301 H314 | EUH 071 | inhalation: ATE = 1,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 220 mg/kg bw’ | |
| ‘612-056-00-9 | N,N-dimethyl-m-toluidine; [1] N,N-dimethyl-o-toluidine [2] | 204-495-6 [1] 210-199-8 [2] | 121-72-2 [1] 609-72-3 [2] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 | H331 H311 H301 H373 ** H412 | GHS06 GHS08 Dgr | H331 H311 H301 H373 ** H412 | * | C’ | |
| ‘613-088-00-6 | 1,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3-one | 220-120-9 | 2634-33-5 | Acute Tox. 2 Acute Tox. 4 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 | H330 H302 H315 H318 H317 H400 H410 | GHS06 GHS05 GHS09 Dgr | H330 H302 H315 H318 H317 H410 | inhalation: ATE = 0,21 mg/L (dusts or mists) oral: ATE = 450 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,036 % M = 1 M = 1’ | ||
| ‘613-127-00-7 | mepiquat chloride (ISO); 1,1-dimethylpiperidinium chloride | 246-147-6 | 24307-26-4 | Acute Tox. 4 Acute Tox. 3 Aquatic Chronic 3 | H332 H301 H412 | GHS06 Dgr | H332 H301 H412 | inhalation: ATE = 2,8 mg/L (dusts or mists) oral: ATE = 270 mg/kg bw’ | ||
| ‘613-307-00-5 | clothianidin (ISO); (E)-1-(2-chloro–1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine | 433-460-1 | 210880-92-5 | Repr. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 | H361f H302 H370 (nervous system) H400 H410 | GHS08 GHS07 GHS09 Dgr | H361f H302 H370 (nervous system) H410 | oral: ATE = 390 mg/kg bw M = 10 M = 100’ | ||
| ‘616-035-00-5 | cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [1] (2E)-2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [2] | 261-043-0 [1] - [2] | 57966-95-7 [1] 166900-80-7 [2] | Repr. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361fd H302 H373 (blood system, thymus, eyes) H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H361fd H302 H373 (blood system, thymus, eyes) H317 H410 | oral: ATE = 360 mg/kg bw M = 1 M = 1’ | ||
| ‘616-104-00-X | benalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate | 275-728-7 | 71626-11-4 | Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H302 H400 H410 | GHS07 GHS09 Wng | H302 H410 | oral: ATE = 1 000 mg/kg bw M = 1 M = 1’ |
ELI: http://data.europa.eu/eli/reg_del/2024/197/oj
ISSN 1977-0677 (electronic edition)
Reading this document does not replace reading the official text published in the Official Journal of the European Union. We assume no responsibility for any inaccuracies arising from the conversion of the original to this format.
This text is published under EUR-Lex's own terms of reuse, not a Legalize or public-domain licence.
EUR-Lex
Creative Commons Attribution 4.0 International (CC BY 4.0)
© European Union, https://eur-lex.europa.eu — Source: EUR-Lex (Publications Office of the European Union). Reused under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Only EU legislation published in the printed Official Journal of the European Union is deemed authentic; consolidated texts are reproduced here for documentation purposes and have been reformatted to Markdown.